Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by C10H12N2on Jul 13, 2022 2:37pm
106 Views
Post# 34821559

Chattering Investment Groups Eh?

Chattering Investment Groups Eh?From stocktwits @boogawooga102 It's old news!!! They have been talking about a July dat dump for months now. PLEASE NAME THE CHATTERING investor groups. Otherwise, what's the point? Algernon must run another Phase 2 study before moving to Phase 3 if ever. The data yet to be released will not move any trial beyond Phase 2. Thus, I'm highly skeptical of any sustained upwards price action other than those selling the news to newbies. Wall Street has rejected throwing money at Algernon's massive dilution lineup of Phase 1 studies. The Chronic Cough angle remains shareholders best chance out of penny world before 2026. Where's the money and timeline for that! Does any of the chattering investment groups have any credible information about that or is everything looked at from a myopic view of penny flipping shares here and there? Where's the real dialog here and every other Algernon message board. It remains non existent that's where.
<< Previous
Bullboard Posts
Next >>